Coherus Oncology (CHRS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Coherus Oncology

NasdaqGM•Healthcare•Biotechnology

$1.42+0.05(0.04%)Market closed

Market Cap

$190.42M

P/S

3.7x

P/B

3.1x

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

How this company scores

PoorMetricSide Score: 19/100

Grade capped at D — Interest coverage below 1× (-17.1x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (7/25); weakest: Growth (0/25).

Profitability5/25

Growth0/25

Balance Sheet & Red Flags7/25

Cash & Earnings Quality7/25

Strengths

Net cash positionImproving margins

Grade capped at D

Interest coverage below 1× (-17.1x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1.2x5y range 0.5x – 6.1x

Currently near its 5-quarter median.

P/S · 3.7x5y range 0.4x – 4.7x

Currently above its 20-quarter median.

P/B · 3.1x5y range 0.7x – 79.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $190.42M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $50.94M
Q. Revenue: $14.31M
TTM EBITDA: $-156.35M
TTM Op. Income: $-158.69M
Q. Op. Income: $-32.33M
TTM Net Income: $-132.13M
Q. Net Income: $-20.63M
EPS: $-0.13
Shares Out.: $154.82M

$50.94M in TTM revenue declined 64.3% YoY, reaching $14.31M last quarter. TTM EBITDA of $-156.35M and TTM operating income of $-158.69M show growth is flowing through to the bottom line. However, net income is negative at $132.13M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 70.4%
EBITDA Margin: -220.0%
Op. Margin: -226.0%
Net Margin: -144.2%

Op. margin of -226.0% is up 217.6% YoY — cost efficiency is improving. Net margin at -144.2% and gross margin of 70.4% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 5 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3.7x
P/B Ratio: 3.1x

P/S of 3.7x and P/B of 3.1x. Over the past year, P/E is down 81% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $191.18M
Cash: $82.92M
Long-Term Debt: N/A
Book Value: $60.84M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-62.09M
TTM Free Cash Flow: $-186.03M
FCF Margin: -365.2%
FCF / Net Income: 1.4

TTM FCF of $-186.03M on $-62.09M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.